[New drugs; pegaptanib and ranibizumab].

摘要: The neovascular ('wet') form of age-related macular degeneration (AMD) is characterized by vascular growth and leakage in the retina. Two new drugs, pegaptanib ranibizumab, have been shown to improve vision or slow progression AMD. Both drugs inhibit action endothelial factor--pegaptanib as an oligonucleotide ranibizumab a monoclonal antibody--thereby decreasing angiogenesis eye. Adverse effects are associated with intravitreal administration both include increased intraocular pressure, local bleeding, infection.